All fields are required
First Name
Last Name
Age
Email
Please repeat your email
Phone
Institution
Position
—Please choose an option—Primary care physician / GeneralistSpeciality physicianNurseNurse practitionerPharmacistPharma professionalClinical ResearcherStudent (PhD, HCP)FellowResident Medical InternSocial workerOther (please specify)
If you selected "Other", please specify
If you selected "Speciality Physician" or "Resident Medical Intern", please specify your speciality
Average number of HIV patients treated per month, if applicable
Years of dedication to the HIV field
City
Country
Grant request
Travel —Please choose an option—YesNo
Accommodation —Please choose an option—YesNo
Motivation
CV
Prior knowledge test
Please, complete the following questionnaire about general HIV Clinical Topics. This test has a purely informative purpose for the organization of the event. Your answers will not be taken into account when reviewing your candidacy as an attendee and/or fellow.
1. Regarding a two-drug regimen with dolutegravir + lamivudine in initial ART, which one is false? —Please choose an option—A. It has proven non-inferiority against dolutegravir + TDF/FTCB. Was associated with significantly lower weight gain than dolutegravir + TDF/FTCC. Resistance was uncommon but did occur with dolutegravir + lamivudineD. There was a benefit in kidney and bone safety with dolutegravir + lamivudine
2. Which one is not considered as a major component of the strategies to reduce HIV transmission?: —Please choose an option—A. Starting ART the sooner the better.B. Achieving and undetectable viral load in those treatedC. Widespread use of PrEP in those at riskD. Using long-acting ART.
3. Which one is expected to constitute a silent liver epidemic among HIV-infected subjects in the upcoming years? —Please choose an option—A. Non-alcoholic steatohepatitisB. Hepatitis C virus infectionC. Hepatitis B virus infectionD. Drug-induced liver toxicity
4. Regarding PrEP use, which one is false? —Please choose an option—A. Using generic TDF/FTC it is a cost-effective strategyB. Daily TDF/FTC is the only approved strategy so far in EU.C. It is associated with a reduction of sexually transmitted infectionsD. Daily PrEP has similar efficacy than on-demand PrEP with TDF/FTC
5. Regarding drug-drug interactions with ART, which one is false: —Please choose an option—A. They can be potentially severe and involve contraindicated drugsB. Antiretroviral drugs are always perpetrators, never victimsC. Interaction with the liver CYP450 enzyme complex is the most common pathway where interactions occurD. Integrase inhibitors can interact with medications containing iron or calcium at a gastric level.
6. Which one should you consider the most important unmet need in ART? —Please choose an option—A. An oral regimen administered once weekly in a single-pillB. A subcutaneous regimen auto-administered monthly or bimonthly by the patientC. A viral remission allowing at least a quarterly treatment interruptionD. A preventative vaccine with a protective efficacy of at least a 50%
I agree to the terms and conditions
